SCHEMBL2880679

SCHEMBL2880679

N#Cc1nn(Cc2ccccc2F)c2ncnc(N)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.58
LRRK2 Q5S007 3/20 0.54
PIK3CD O00329 12/20 0.48
PIK3CG P48736 6/20 0.43
PIK3CA P42336 4/20 0.43
PIK3CB P42338 4/20 0.43
PRKDC P78527 4/20 0.43
ABL1 P00519 3/20 0.43
EGFR P00533 3/20 0.43
HCK P08631 3/20 0.43
SRC P12931 3/20 0.43
KDR P35968 3/20 0.43
MTOR P42345 3/20 0.43
EPHB4 P54760 3/20 0.43
PI4KB Q9UBF8 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PIK3C2B O00750 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682446 0.81 PIK3CD (0.71) PIK3CDPIK3CGPIK3C2B
SCHEMBL15169434 0.77 PDE5A (0.50) BTKLRRK2ABL1SRCMEN1
SCHEMBL2881160 0.76 BTK (0.55) BTKLRRK2PIK3CDPIK3CGPIK3CA
SCHEMBL2881157 0.76 BTK (0.55) BTKLRRK2PIK3CDPIK3CGPIK3CA
SCHEMBL8226946 0.76 BTK (0.55) BTKLRRK2PIK3CDPIK3CGPIK3CA
SCHEMBL19727231 0.76 PIK3CG (0.54) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL21775364 0.75 ALDH1A1 (0.41) BTKLRRK2MEN1ALDH1A1KMT2A
SCHEMBL2881164 0.75 BTK (0.54) BTKLRRK2PIK3CDPIK3CGPIK3CA
SCHEMBL6868182 0.75 BTK (0.62) BTKPIK3CDPIK3CGPIK3CAPIK3CB
SCHEMBL2878149 0.75 TSHR (0.47) BTKLRRK2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004235-A1 Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004235-A1 Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004235-A1 Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
WO-2007124854-A1 HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES BAYER HEALTHCARE AG (DE) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004235-A1 Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses AADAC, CYP11B2, PC BTK 3577/4885LRRK2 4503/4885PIK3CD 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.